Rapamycin’s Impact on Age-Related Macular Degeneration—A Systematic Review and Hormesis Perspective
Open Access
- 17 September 2024
- journal article
- review article
- Published by MDPI AG in Journal of Clinical & Translational Ophthalmology
- Vol. 2 (3) , 99-112
Abstract
Background: Pre-clinical studies related to the use of rapamycin (Sirolimus®), a mammalian target of rapamycin (mTOR) inhibitors, for age-related macular degeneration (AMD) have shown improved therapeutic outcomes. However, knowledge of its dose–effect relationship in humans with AMD has been limited and requires further investigation. Objective: The aim of this study is to assess the safety and efficacy of Sirolimus® for treatment of AMD in humans and determine the dose range for its application in the eye. Methods: A systematic literature review was conducted following the PRISMA guidelines. The MEDLINE, Embase, CINAHL, Scopus and Cochrane Central Registry of Controlled Trials databases were searched for original clinical studies examining the effects of Sirolimus® on outcomes linked to AMD in humans. This review has been registered in the PROSPERO database. Results: Only four studies were found to satisfy the inclusion and exclusion criteria and were analyzed in this systematic review in a narrative way. The dose range of rapamycin in the limited number of studies appears to be toxic to the retina. Conclusion: Future studies should focus on establishing the optimal low-dose range of Sirolimus® that effectively induces autophagy without causing retinal toxicity, as current data indicate a potential therapeutic window that remains underexplored. Specifically, longitudinal, controlled studies with larger, heterogeneous patient populations are necessary to determine the precise dosing that balances efficacy and safety in treating AMD.Keywords
This publication has 32 references indexed in Scilit:
- Neovascular Progression and Retinal Dysfunction in the Laser-Induced Choroidal Neovascularization Mouse ModelBiomedicines, 2023
- The Impact of Hormesis, Neuronal Stress Response, and Reproduction, upon Clinical Aging: A Narrative ReviewJournal of Clinical Medicine, 2023
- Prevalence of Age-Related Macular Degeneration in the US in 2019JAMA Ophthalmology, 2022
- The effect of rapamycin and its analogues on age-related musculoskeletal diseases: a systematic reviewAging Clinical and Experimental Research, 2022
- Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery SystemsPharmaceutics, 2022
- Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS studyInternational Ophthalmology, 2021
- Autophagy regulates death of retinal pigment epithelium cells in age-related macular degenerationCell Biology and Toxicology, 2016
- Prevention of Age-Related Macular Degeneration–Like Retinopathy by Rapamycin in RatsThe American Journal of Pathology, 2012
- A Randomized, Dose-Escalation Study of Subconjunctival and Intravitreal Injections of Sirolimus in Patients with Diabetic Macular EdemaOphthalmology, 2012
- Hormesis in agingAgeing Research Reviews, 2008